

**All ETCTN Trials: Updated April 24, 2024 (Includes trials that are in review, approved, and active)**

<b>CTEP Trial ID</b>	<b>Title</b>	<b>Limited/ETCTN-wide</b>	<b>Radiation Oncology</b>	<b>Disease Area(s)</b>	<b>ClinicalTrials.gov website (if available)</b>
10075	A Phase 1B Study of KRT-232 (AMG-232) in Combination with Decitabine in Acute Myeloid Leukemia	ETCTN-wide		Leukemia	<a href="https://clinicaltrials.gov/ct2/show/NCT03041688">https://clinicaltrials.gov/ct2/show/NCT03041688</a>
10076	A Phase 1 Dose-Escalation and Exploratory Dose Expansion Study of AMG 232 in Combination with Carfilzomib, Lenalidomide, and Dexamethasone in Relapsed and/or Refractory Myeloma	Limited		Myeloma	<a href="https://clinicaltrials.gov/ct2/show/NCT03031730">https://clinicaltrials.gov/ct2/show/NCT03031730</a>
10096	A Phase 1/2 Study of Combination Olaparib and Radium-223 in Men with Metastatic Castration-Resistant Prostate Cancer with Bone Metastases (COMRADE)	ETCTN-wide	Radiation	Genitourinary	<a href="https://clinicaltrials.gov/ct2/show/NCT03317392">https://clinicaltrials.gov/ct2/show/NCT03317392</a>
10144	A Phase II Study of Olaparib (AZD2281) in Patients with Metastatic/Advanced Urothelial Carcinoma and other genitourinary tumors with DNA-Repair Defects	ETCTN-wide		Genitourinary	<a href="https://clinicaltrials.gov/ct2/show/NCT03375307">https://clinicaltrials.gov/ct2/show/NCT03375307</a>
10146	Randomized phase 2 clinical trial of nab-paclitaxel + MEDI4736 (durvalumab) + tremelimumab + neoantigen vaccine vs. nab-paclitaxel + MEDI4736 (durvalumab) + tremelimumab in patients with metastatic triple negative breast cancer	ETCTN-wide		Breast	<a href="https://clinicaltrials.gov/ct2/show/NCT03606967">https://clinicaltrials.gov/ct2/show/NCT03606967</a>
10186	A Phase I/II Study of Nivolumab Plus or Minus Ipilimumab in Combination with Multi-Fraction Stereotactic Radiosurgery for Recurrent High-Grade Radiation-Relapsed Meningioma	ETCTN-wide	Radiation	Brain	<a href="https://clinicaltrials.gov/ct2/show/NCT03604978">https://clinicaltrials.gov/ct2/show/NCT03604978</a>

**All ETCTN Trials: Updated April 24, 2024 (Includes trials that are in review, approved, and active)**

<b>CTEP Trial ID</b>	<b>Title</b>	<b>Limited/ETCTN-wide</b>	<b>Radiation Oncology</b>	<b>Disease Area(s)</b>	<b>ClinicalTrials.gov website (if available)</b>
10204	Phase Ib Study of Nivolumab in Patients with Autoimmune Disorders and Advanced Malignancies (AIM-NIVO)	ETCTN-wide		Solid tumors (no specified mutations)	<a href="https://clinicaltrials.gov/ct2/show/NCT03816345">https://clinicaltrials.gov/ct2/show/NCT03816345</a>
10214	Immune Checkpoint Blockade for Kidney Transplant Recipients with Selected Unresectable or Metastatic Cancers	ETCTN-wide		Skin and other melanoma	<a href="https://clinicaltrials.gov/ct2/show/NCT03816332">https://clinicaltrials.gov/ct2/show/NCT03816332</a>
10216	A Phase Ib/II Study of Osimertinib and CB-839 in Patients with EGFR Mutant Non-Small Cell Lung Cancer	ETCTN-wide		Lung	<a href="https://clinicaltrials.gov/ct2/show/NCT03831932">https://clinicaltrials.gov/ct2/show/NCT03831932</a>
10273	A Phase I Study of M3814 in Combination with MEC in Patients with Relapsed or Refractory Acute Myeloid Leukemia	ETCTN-wide		Leukemia	<a href="https://clinicaltrials.gov/ct2/show/NCT03983824">https://clinicaltrials.gov/ct2/show/NCT03983824</a>
10276	A Phase I/II Study of M3814 and Avelumab in Combination with Hypofractionated Radiation in Patients with Advanced/Metastatic Solid Tumors and Hepatobiliary Malignancies	ETCTN-wide (in PII)	Radiation	Gastrointestinal, Solid tumors (dose escalation)	<a href="https://clinicaltrials.gov/ct2/show/NCT04068194">https://clinicaltrials.gov/ct2/show/NCT04068194</a>
10285	Phase 1/2 Study of an EZH2 Inhibitor (Tazemetostat) in Combination with Dual BRAF/MEK Inhibition in Patients with BRAF- Mutated Metastatic Melanoma who Progressed on Prior BRAF/MEK Inhibitor Therapy	ETCTN-wide		Skin and other melanoma	<a href="https://clinicaltrials.gov/ct2/show/NCT04557956?id=10285">https://clinicaltrials.gov/ct2/show/NCT04557956?id=10285</a>
10292	DURVA+ : Evaluation of the Safety and Pharmacodynamics of Anti-PD-L1 Antibody MEDI4736 (Durvalumab) in Combination with Chemotherapy in Patients with Advanced Solid Tumors	ETCTN-wide		Solid tumors (no specified mutations)	<a href="https://clinicaltrials.gov/ct2/show/NCT03907475">https://clinicaltrials.gov/ct2/show/NCT03907475</a>
10299	A Phase I Study to Investigate the Safety of the Ubiquitin Activating Enzyme	ETCTN-wide		Lymphoma, Solid tumors (no specified mutations)	<a href="https://clinicaltrials.gov/study/NCT06223542">https://clinicaltrials.gov/study/NCT06223542</a>

**All ETCTN Trials: Updated April 24, 2024 (Includes trials that are in review, approved, and active)**

<b>CTEP Trial ID</b>	<b>Title</b>	<b>Limited/ETCTN-wide</b>	<b>Radiation Oncology</b>	<b>Disease Area(s)</b>	<b>ClinicalTrials.gov website (if available)</b>
	Inhibitor TAK-243 in Adult Solid Tumor and Lymphoma Patients				
10300	BLAST MRD AML-1: A Randomized Phase 2 Study of the Anti-PD-1 Antibody Pembrolizumab in Combination with Conventional Intensive Chemotherapy as Frontline Therapy in Patients with Acute Myeloid Leukemia	ETCTN-wide		Leukemia	<a href="https://clinicaltrials.gov/ct2/show/NCT04214249">https://clinicaltrials.gov/ct2/show/NCT04214249</a>
10301	A Phase I and Randomized Phase II Trial of Radium-223 Dichloride, M3814, & Avelumab in Advanced Metastatic Castrate-Resistant Prostate Cancer (mCRPC)	ETCTN-wide	Radiation	Genitourinary	<a href="https://clinicaltrials.gov/ct2/show/NCT04071236">https://clinicaltrials.gov/ct2/show/NCT04071236</a>
10302	Phase II Trial of Radium-223 Dichloride in Combination with Paclitaxel in Patients with Bone Metastatic Breast Cancer	ETCTN-wide	Radiation	Breast	<a href="https://clinicaltrials.gov/ct2/show/NCT04090398">https://clinicaltrials.gov/ct2/show/NCT04090398</a>
10324	A Phase I/Ib Dose Escalation Study of Pegylated Liposomal Doxorubicin (PLD) with M3814 in Platinum - Resistant or Ineligible Ovarian and Related Cancers with Planned Expansions in High Grade Serous (HGSOC) and Low Grade Serous Ovarian Cancer (LGSOC)	ETCTN-wide		Gynecologic	<a href="https://clinicaltrials.gov/ct2/show/NCT04092270">https://clinicaltrials.gov/ct2/show/NCT04092270</a>
10327	A Phase I Trial of MLN0128(TAK-228) and CB-839 HCL (telaglenastat) in Advanced NSCLC Patients	ETCTN-wide		Lung	<a href="https://clinicaltrials.gov/ct2/show/NCT04250545">https://clinicaltrials.gov/ct2/show/NCT04250545</a>
10330	A Phase 2 Study of Belinostat and SGI-110 (Guadecitabine) for the Treatment of Unresectable and Metastatic Conventional Chondrosarcoma	ETCTN-wide		Sarcoma	<a href="https://clinicaltrials.gov/ct2/show/NCT04340843">https://clinicaltrials.gov/ct2/show/NCT04340843</a>

**All ETCTN Trials: Updated April 24, 2024 (Includes trials that are in review, approved, and active)**

<b>CTEP Trial ID</b>	<b>Title</b>	<b>Limited/ETCTN-wide</b>	<b>Radiation Oncology</b>	<b>Disease Area(s)</b>	<b>ClinicalTrials.gov website (if available)</b>
10335	A Phase 1 Study of Lenalidomide in Combination with EPOCH Chemotherapy for HTLV-Associated Adult T-Cell Leukemia-Lymphoma (ATLL)	ETCTN-wide		Leukemia, Lymphoma	<a href="https://clinicaltrials.gov/ct2/show/NCT04301076">https://clinicaltrials.gov/ct2/show/NCT04301076</a>
10347	A phase I study with an expansion cohort of duvelisib and nivolumab in mycosis fungoides (MF) and Sézary syndrome (SS)	ETCTN-wide		Lymphoma	<a href="https://clinicaltrials.gov/ct2/show/NCT04652960">https://clinicaltrials.gov/ct2/show/NCT04652960</a>
10355	A Phase I Study of DS-8201a in Combination with Olaparib in HER2-Expressing Malignancies	ETCTN-wide		Solid tumors (mutations), solid tumor (dose escalation), gynecologic	<a href="https://clinicaltrials.gov/ct2/show/NCT04585958">https://clinicaltrials.gov/ct2/show/NCT04585958</a>
10358	Phase 1/1B study of DS8201a in combination with ATR Inhibition (AZD6738) in advanced solid tumors with HER2 expression (DASH Trial)	ETCTN-wide		Gastrointestinal, Solid tumors (dose escalation), Solid tumors (mutations)	<a href="https://clinicaltrials.gov/ct2/show/NCT04704661">https://clinicaltrials.gov/ct2/show/NCT04704661</a>
10366	A Phase 1/2 Study of M3814 (Peposertib) in Combination with Hypofractionated Radiotherapy for the Treatment of Locally Advanced Pancreatic Adenocarcinoma	ETCTN-wide	Radiation	Gastrointestinal	<a href="https://clinicaltrials.gov/ct2/show/NCT04172532">https://clinicaltrials.gov/ct2/show/NCT04172532</a>
10371	A Pharmacodynamics-Driven Trial of Talazoparib, an Oral PARP Inhibitor, in Patients with Advanced Solid Tumors and Aberrations in Genes Involved in DNA Damage Response	ETCTN-wide		Solid tumors (mutations)	<a href="https://clinicaltrials.gov/ct2/show/NCT04550494">https://clinicaltrials.gov/ct2/show/NCT04550494</a>
10401	A Phase 0 window-of-opportunity pharmacodynamic trial of triapine (NSC# 663249) in uterine corpus serous adenocarcinoma	ETCTN-wide		Gynecologic	<a href="https://clinicaltrials.gov/ct2/show/NCT04494113">https://clinicaltrials.gov/ct2/show/NCT04494113</a>

All ETCTN Trials: Updated April 24, 2024 (Includes trials that are in review, approved, and active)

<b>CTEP Trial ID</b>	<b>Title</b>	<b>Limited/ETCTN-wide</b>	<b>Radiation Oncology</b>	<b>Disease Area(s)</b>	<b>ClinicalTrials.gov website (if available)</b>
10422	Abemaciclib and Olaparib for Recurrent Ovarian Cancer	ETCTN-wide		Gynecologic	<a href="https://clinicaltrials.gov/ct2/show/NCT04633239?id=10422">https://clinicaltrials.gov/ct2/show/NCT04633239?id=10422</a>
10434	Randomized Phase 2 Study of CPX-351 + Pomalidomide versus CPX-351 in Newly Diagnosed AML with MDS-Related Changes	ETCTN-wide		Leukemia	<a href="https://clinicaltrials.gov/ct2/show/NCT04802161">https://clinicaltrials.gov/ct2/show/NCT04802161</a>
10433	Phase I/Ib trial evaluating the safety and efficacy of BET inhibitor, ZEN003694 with PD-1 inhibitor, nivolumab with or without CTLA-4 inhibitor, ipilimumab in solid tumors	ETCTN-wide		Solid tumors (no specified mutations), Gynecologic	<a href="https://clinicaltrials.gov/ct2/show/NCT04840589">https://clinicaltrials.gov/ct2/show/NCT04840589</a>
10440	A Phase 1/1a Study of Venetoclax, MLN9708 (Ixazomib Citrate) and Dexamethasone for Relapsed/Refractory Light Chain Amyloidosis	ETCTN-wide		Myeloma	<a href="https://clinicaltrials.gov/ct2/show/NCT04847453">https://clinicaltrials.gov/ct2/show/NCT04847453</a>
10466	A Phase II Study of Bevacizumab, Erlotinib and Atezolizumab in Subjects with Advanced Hereditary Leiomyomatosis and Renal Cell Cancer (HLRCC) Associated or Sporadic Papillary Renal Cell Cancer	ETCTN-wide		Genitourinary	<a href="https://clinicaltrials.gov/ct2/show/NCT04981509">https://clinicaltrials.gov/ct2/show/NCT04981509</a>
10483	Phase Ib Trial of Erdafitinib Combined with Enfortumab Vedotin Following Platinum and PD1/L1 Inhibitors for Metastatic Urothelial Carcinoma with FGFR2/3 Genetic Alterations	ETCTN-wide		Genitourinary	<a href="https://clinicaltrials.gov/ct2/show/NCT04963153">https://clinicaltrials.gov/ct2/show/NCT04963153</a>
10445	Phase I Dose Escalation and Expansion Study of Tazemetostat in Combination with Topotecan and Pembrolizumab in Extensive-Stage Small Cell Lung Cancer	ETCTN-wide		Lung	<a href="https://clinicaltrials.gov/ct2/show/NCT05353439">https://clinicaltrials.gov/ct2/show/NCT05353439</a>
10499	Phase Ib/II Study of ZEN003694 and Entinostat in Advanced and Refractory Solid Tumors and Lymphomas	ETCTN-wide		Lymphoma, Solid tumors (no specified mutations)	<a href="https://clinicaltrials.gov/ct2/show/NCT05053971">https://clinicaltrials.gov/ct2/show/NCT05053971</a>

**All ETCTN Trials: Updated April 24, 2024 (Includes trials that are in review, approved, and active)**

<b>CTEP Trial ID</b>	<b>Title</b>	<b>Limited/ETCTN-wide</b>	<b>Radiation Oncology</b>	<b>Disease Area(s)</b>	<b>ClinicalTrials.gov website (if available)</b>
10507	A Phase 1/2 Study of the Bromodomain Inhibitor ZEN003694 in Combination with Etoposide/Platinum in Patients with NUT Carcinoma	ETCTN-wide		Sarcoma	<a href="https://clinicaltrials.gov/ct2/show/NCT05019716">https://clinicaltrials.gov/ct2/show/NCT05019716</a>
10490	Rapid Analysis and Response Evaluation of Combination Anti-Neoplastic Agents in Rare Tumors (RARE CANCER) Trial: RARE 2 Talazoparib and Temozolomide	ETCTN-wide		Solid tumors (no specified mutations)	<a href="https://clinicaltrials.gov/ct2/show/NCT05142241">https://clinicaltrials.gov/ct2/show/NCT05142241</a>
10492	Phase I/Ib Study of AKT Inhibitor Ipatasertib with Chemoradiation for Locally Advanced Head and Neck Cancer	ETCTN-wide	Radiation	Head and neck	<a href="https://clinicaltrials.gov/ct2/show/NCT05172245">https://clinicaltrials.gov/ct2/show/NCT05172245</a>
10496	A Phase II Trial of Ipatasertib in Combination with Pembrolizumab for First Line Treatment of Recurrent or Metastatic Squamous Cell Cancer of the Head and Neck	ETCTN-wide		Head and neck	<a href="https://clinicaltrials.gov/ct2/show/NCT05172258">https://clinicaltrials.gov/ct2/show/NCT05172258</a>
10486	Phase 2 Trial of the Combination of the BET Inhibitor, ZEN-3694, and the PARP Inhibitor Talazoparib, in Patients with Molecularly-Selected Solid Tumors (ComBET)	ETCTN-wide		Solid tumors (no specified mutations)	<a href="https://clinicaltrials.gov/ct2/show/NCT05327010">https://clinicaltrials.gov/ct2/show/NCT05327010</a>
10495	Phase I Trial of DS-8201a (Trastuzumab Deruxtecan) in Combination with Neratinib in Solid Tumors with HER2 Alterations	ETCTN-wide		Solid tumors (no specified mutations)	<a href="https://clinicaltrials.gov/ct2/show/NCT05372614">https://clinicaltrials.gov/ct2/show/NCT05372614</a>
10504	A Phase 2 Study of Atezolizumab with or Without Selinexor in Alveolar Soft Part Sarcoma (AXIOM)	ETCTN-wide		Sarcoma	<a href="https://clinicaltrials.gov/ct2/show/NCT05333458">https://clinicaltrials.gov/ct2/show/NCT05333458</a>

**All ETCTN Trials: Updated April 24, 2024 (Includes trials that are in review, approved, and active)**

<b>CTEP Trial ID</b>	<b>Title</b>	<b>Limited/ETCTN-wide</b>	<b>Radiation Oncology</b>	<b>Disease Area(s)</b>	<b>ClinicalTrials.gov website (if available)</b>
10508	A Phase 1/2 Study of the Combination of Oral DNMT Inhibition and Checkpoint Inhibition in Relapsed DLBCL and HL	ETCTN-wide		Lymphoma	<a href="https://clinicaltrials.gov/ct2/show/NCT05272384">https://clinicaltrials.gov/ct2/show/NCT05272384</a>
10449	A Phase 1 Study of ZEN003694 in Combination with Binimetinib in Solid Tumors with RAS Pathway Alterations and Triple Negative Breast Cancer	Limited (for dose escalation)		Breast	<a href="https://clinicaltrials.gov/ct2/show/NCT05111561">https://clinicaltrials.gov/ct2/show/NCT05111561</a>
10509	A Phase 1 Study of BET Bromodomain Inhibitor ZEN003694 in Combination with the CDK4/6 Inhibitor Abemaciclib in Patients with NUT Carcinoma and Other Solid Tumors	ETCTN-wide		ST escalation, Sarcoma	<a href="https://clinicaltrials.gov/ct2/show/NCT05372640">https://clinicaltrials.gov/ct2/show/NCT05372640</a>
10512	A Phase 2 Randomized Study of the BER Inhibitor TRC102 in Combination with Standard Pemetrexed-Platinum-Radiation in Stage III Non-Squamous Non-Small Cell Lung Cancer	ETCTN-wide	Radiation	Lung	<a href="https://clinicaltrials.gov/ct2/show/NCT05198830">https://clinicaltrials.gov/ct2/show/NCT05198830</a>
10237	A Phase 1 Study of MLN7243 (TAK-243) for Either Relapsed/Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome/Chronic Myelomonocytic Leukemia Refractory to Hypomethylating Agents	Limited		Leukemia	<a href="https://clinicaltrials.gov/ct2/show/NCT03816319">https://clinicaltrials.gov/ct2/show/NCT03816319</a>
10464	A Phase 1 Study of Olaparib in Combination with Durvalumab (MEDI4736) and Concurrent Radiation Therapy Following First-Line Chemotherapy in Locally Advanced Unresectable Pancreatic Cancer	ETCTN-wide		Gastrointestinal	<a href="https://clinicaltrials.gov/ct2/show/NCT05411094">https://clinicaltrials.gov/ct2/show/NCT05411094</a>
10525	A Phase 1b Trial of ZEN-3694 with Pembrolizumab and Nab-Paclitaxel in	ETCTN-wide		Breast	<a href="https://clinicaltrials.gov/ct2/show/NCT05422794">https://clinicaltrials.gov/ct2/show/NCT05422794</a>



**All ETCTN Trials: Updated April 24, 2024 (Includes trials that are in review, approved, and active)**

<b>CTEP Trial ID</b>	<b>Title</b>	<b>Limited/ ETCTN- wide</b>	<b>Radiation Oncology</b>	<b>Disease Area(s)</b>	<b>ClinicalTrials.gov website (if available)</b>
	Patients with Metastatic Triple-Negative Breast Cancer				
10487	A Phase II Study of Lutetium Lu 177 Dotatate in Metastatic Prostate Cancer with Neuroendocrine Differentiation	ETCTN-wide		Genitourinary, Endocrine	<a href="https://clinicaltrials.gov/ct2/show/NCT05691465">https://clinicaltrials.gov/ct2/show/NCT05691465</a>
10500	Phase 1/Expansion study of tazemetostat plus belinostat for the treatment of relapsed or refractory lymphoma	ETCTN-wide		Lymphoma	<a href="https://clinicaltrials.gov/ct2/show/NCT05627245">https://clinicaltrials.gov/ct2/show/NCT05627245</a>
10528	Phase 1 study of the POLq inhibitor Novobiocin in BRCA-mutant and other DNA damage repair-deficient solid tumors	ETCTN-wide		ST Mutations	<a href="https://clinicaltrials.gov/ct2/show/NCT05687110">https://clinicaltrials.gov/ct2/show/NCT05687110</a>
10479	A Phase I Dose Escalation-Expansion Trial of Sunitinib Malate plus Lutetium Lu 177 Dotatate (Lutathera) in Somatostatin Receptor Positive Pancreatic Neuroendocrine Tumors	ETCTN-wide		Endocrine, Gastrointestinal	<a href="https://clinicaltrials.gov/ct2/show/NCT05687123">https://clinicaltrials.gov/ct2/show/NCT05687123</a>
10505	A Phase 1/2 Trial of Selinexor and Temozolomide in Recurrent Glioblastoma	ETCTN-wide		Brain	<a href="https://clinicaltrials.gov/ct2/show/NCT05432804">https://clinicaltrials.gov/ct2/show/NCT05432804</a>
10527	A Molecularly Driven Phase 1b Dose Escalation and Dose Expansion Study of the DNA-PK Inhibitor Peposertib (M3814) in Combination with the ATR Inhibitor M1774	ETCTN-wide		ST Mutations	<a href="https://clinicaltrials.gov/ct2/show/NCT05687136">https://clinicaltrials.gov/ct2/show/NCT05687136</a>
10522	A Phase I Clinical Trial of CA-4948 in Combination with Gemcitabine and Nab-Paclitaxel in Metastatic or Unresectable Pancreatic Ductal Carcinoma	ETCTN-wide		Gastrointestinal	<a href="https://clinicaltrials.gov/ct2/show/NCT05685602">https://clinicaltrials.gov/ct2/show/NCT05685602</a>



**All ETCTN Trials: Updated April 24, 2024 (Includes trials that are in review, approved, and active)**

<b>CTEP Trial ID</b>	<b>Title</b>	<b>Limited/ETCTN-wide</b>	<b>Radiation Oncology</b>	<b>Disease Area(s)</b>	<b>ClinicalTrials.gov website (if available)</b>
10538	Venetoclax In Combination with ASTX727, an All-ORal Therapy for Chronic Myelomonocytic Leukemia and Other MDS/MPN with Excess Blasts (VICTORY-MDS/MPN): a Randomized, Phase 2 Trial	ETCTN-wide		Leukemia	<a href="https://clinicaltrials.gov/ct2/show/NCT05600894">https://clinicaltrials.gov/ct2/show/NCT05600894</a>
10546	Targeting DNA Methyltransferases in Metastatic Triple-Negative Breast Cancer	ETCTN-wide		Breast	<a href="https://clinicaltrials.gov/ct2/show/NCT05673200">https://clinicaltrials.gov/ct2/show/NCT05673200</a>
10553	A Phase II Clinical and Biomarker Study of Darolutamide in Combination with Androgen Deprivation Therapy (ADT) for Hormone-Therapy Naïve Recurrent and/or Metastatic Androgen Receptor (AR) Positive Salivary Gland Cancer Patients	ETCTN-wide		Head and Neck	<a href="https://clinicaltrials.gov/ct2/show/NCT05669664">https://clinicaltrials.gov/ct2/show/NCT05669664</a>
10558	A phase II randomized control trial of triapine plus lutetium 177 dotatate versus lutetium 177 dotatate alone for well-differentiated somatostatin receptor-positive neuroendocrine tumors	ETCTN-wide		Endocrine	<a href="https://clinicaltrials.gov/ct2/show/NCT05724108">https://clinicaltrials.gov/ct2/show/NCT05724108</a>
10561	Rapid Analysis and Response Evaluation of Combination Anti-neoplastic Agents in Rare Tumors (RARE CANCER) Trial: RARE 3 Tiragolumab + Atezolizumab	Limited		Solid Tumors, NOS	<a href="https://clinicaltrials.gov/ct2/show/NCT05715281">https://clinicaltrials.gov/ct2/show/NCT05715281</a>
10563	A phase 1 study of pepsertib (M3814) and low-dose liposomal doxorubicin (Doxil®) in patients with metastatic leiomyosarcoma and other soft tissue sarcomas	ETCTN-wide		Sarcoma	<a href="https://clinicaltrials.gov/ct2/show/NCT05711615">https://clinicaltrials.gov/ct2/show/NCT05711615</a>

**All ETCTN Trials: Updated April 24, 2024 (Includes trials that are in review, approved, and active)**

<b>CTEP Trial ID</b>	<b>Title</b>	<b>Limited/ ETCTN-wide</b>	<b>Radiation Oncology</b>	<b>Disease Area(s)</b>	<b>ClinicalTrials.gov website (if available)</b>
10556	Randomized Phase 2 Study of Cabozantinib, Ipilimumab, and Nivolumab in Patients with Soft Tissue Sarcoma	ETCTN-wide		Sarcoma	<a href="https://clinicaltrials.gov/ct2/show/NCT05836571">https://clinicaltrials.gov/ct2/show/NCT05836571</a>
10597	A Phase 1 trial of APG-1252 (pelcitoclax) and cobimetinib in recurrent ovarian and endometrial cancers	ETCTN-wide		Gynecologic	<a href="https://clinicaltrials.gov/ct2/show/NCT05691504">https://clinicaltrials.gov/ct2/show/NCT05691504</a>
10577	Pilot Study of CBX-12 Pharmacodynamics in Patients with Advanced Solid Tumors	Limited		Solid tumor (no specified mutations)	<a href="https://clinicaltrials.gov/ct2/show/NCT05691517">https://clinicaltrials.gov/ct2/show/NCT05691517</a>
10572	A Phase 1 Trial Evaluating the Combination of Temozolomide and the Ataxia Telangiectasia and Rad3-Related Inhibitor M1774	Limited		ST Mutations	<a href="https://clinicaltrials.gov/ct2/show/NCT05691491">https://clinicaltrials.gov/ct2/show/NCT05691491</a>
10590	A Phase 2 Study of Mosunetuzumab or Rituximab in Nodular Lymphocyte-Predominant Hodgkin Lymphoma	ETCTN-wide		Lymphoma	<a href="https://clinicaltrials.gov/ct2/show/NCT05886036">https://clinicaltrials.gov/ct2/show/NCT05886036</a>
10596	A Phase 1b Study of Menin Inhibitor SNDX-5613 in Combination with Daunorubicin and Cytarabine in Newly Diagnosed Patients with Acute Myeloid Leukemia and NPM1 Mutated/FLT3 Wildtype or MLL Rearranged Disease	ETCTN-wide		Leukemia	<a href="https://clinicaltrials.gov/ct2/show/NCT05886049">https://clinicaltrials.gov/ct2/show/NCT05886049</a>
10579	Phase I Trial of ZEN003694 (ZEN-3694) in Combination with Capecitabine in Patients with Solid Tumors	Limited		Solid tumors (dose escalation), GI	<a href="https://clinicaltrials.gov/ct2/show/NCT05803382">https://clinicaltrials.gov/ct2/show/NCT05803382</a>
10601	A Phase 1 Study of Mosunetuzumab with Polatuzumab Vedotin and Lenalidomide (M+Pola+Len) in	ETCTN-wide		Lymphoma	<a href="https://clinicaltrials.gov/study/NCT06015880">https://clinicaltrials.gov/study/NCT06015880</a>

All ETCTN Trials: Updated April 24, 2024 (Includes trials that are in review, approved, and active)

<b>CTEP Trial ID</b>	<b>Title</b>	<b>Limited/ETCTN-wide</b>	<b>Radiation Oncology</b>	<b>Disease Area(s)</b>	<b>ClinicalTrials.gov website (if available)</b>
	Relapsed/Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL)				
10559	A Phase 2 Study of Erdafitinib in Patients with Recurrent or Progressive IDH-Wild Type Glioma with FGFR-TACC Gene Fusion	ETCTN-wide		Brain	<a href="https://clinicaltrials.gov/ct2/show/NCT05859334">https://clinicaltrials.gov/ct2/show/NCT05859334</a>
10603	Phase II Study of M1774 in Refractory SPOP-Mutant Prostate Cancer	ETCTN-wide		Genitourinary	<a href="https://clinicaltrials.gov/ct2/show/NCT05828082">https://clinicaltrials.gov/ct2/show/NCT05828082</a>
10592	A Phase 2 Study of ATR Inhibition in Advanced PD-(L)1-Refractory Merkel Cell Carcinoma	ETCTN-wide		Skin and other melanoma	<a href="https://clinicaltrials.gov/study/NCT05947500">https://clinicaltrials.gov/study/NCT05947500</a>
10614	A Phase 1/2 Study of Nivolumab and Ipilimumab in Combination with Sirolimus and Prednisone in Kidney Transplant Recipients with Selected Unresectable or Metastatic Cutaneous Cancers	ETCTN-wide		Skim and other melanoma	<a href="https://clinicaltrials.gov/ct2/show/NCT05896839">https://clinicaltrials.gov/ct2/show/NCT05896839</a>
10605	Phase I Trial of ZEN-3694 in Combination with Cetuximab and Encorafenib in Patients with Refractory BRAF V600E Metastatic Colorectal Cancer	ETCTN-wide		Gastrointestinal	<a href="https://clinicaltrials.gov/study/NCT06102902">https://clinicaltrials.gov/study/NCT06102902</a>
10608	A Phase II Trial of Durvalumab with Gemcitabine and Cisplatin as Neoadjuvant Therapy for High-Risk Resectable Intrahepatic Cholangiocarcinoma	ETCTN-wide		Gastrointestinal	<a href="https://clinicaltrials.gov/study/NCT06050252">https://clinicaltrials.gov/study/NCT06050252</a>

All ETCTN Trials: Updated April 24, 2024 (Includes trials that are in review, approved, and active)

<b>CTEP Trial ID</b>	<b>Title</b>	<b>Limited/ ETCTN- wide</b>	<b>Radiation Oncology</b>	<b>Disease Area(s)</b>	<b>ClinicalTrials.gov website (if available)</b>
10612	A Randomized Phase 2 Study of Daratumumab-Selinexor-Velcade-Dexamethasone (Dara-SVD) for High-Risk Newly Diagnosed Multiple Myeloma	ETCTN-wide		Myeloma	<a href="https://clinicaltrials.gov/study/NCT06169215">https://clinicaltrials.gov/study/NCT06169215</a>
10629	A Phase I Dose Finding and Phase II Randomized Trial of Iadademstat Combined with Immune Checkpoint Inhibition Maintenance After Initial Chemoimmunotherapy in Patients with Extensive-Stage Small Cell Lung Cancer	ETCTN-wide		Lung	<a href="https://clinicaltrials.gov/study/NCT06287775">https://clinicaltrials.gov/study/NCT06287775</a>
10640	Phase 2 and Biomarker Trial of Anti-TIGIT and Anti-PDL1 in Patients with Recurrent Glioblastoma	ETCTN-wide		Brain	<a href="https://clinicaltrials.gov/study/NCT06328036">https://clinicaltrials.gov/study/NCT06328036</a>
10653	A phase I study of Lintuzumab-Ac-225 in combination with venetoclax and ASTX-727 in adults with newly diagnosed AML	ETCTN-wide		Leukemia	Not available currently.
10637	Phase 2 Trial of Venetoclax in Classic or Variant Hairy Cell Leukemia	Limited		Leukemia	<a href="https://clinicaltrials.gov/study/NCT06311227">https://clinicaltrials.gov/study/NCT06311227</a>
10554	Phase 1 Study of Trastuzumab Deruxtecan (DS-8201a) in Combination with Azenosertib (ZN-c3) in HER2-Expressing/Amplified Cyclin E-Amplified Gastric/Gastroesophageal Junction Cancer and Other Solid Tumors with HER2 Expression	Limited for escalation; wide for expansion		Gastrointestinal; Solid tumors (dose escalation)	<a href="https://clinicaltrials.gov/study/NCT06364410">https://clinicaltrials.gov/study/NCT06364410</a>
10667	Pilot Study of Pidnarulex Pharmacodynamics in Patients with Advanced Solid Tumors	Limited		Solid Tumors, NOS	Not available currently.

**All ETCTN Trials: Updated April 24, 2024 (Includes trials that are in review, approved, and active)**

<b>CTEP Trial ID</b>	<b>Title</b>	<b>Limited/ ETCTN- wide</b>	<b>Radiation Oncology</b>	<b>Disease Area(s)</b>	<b>ClinicalTrials.gov website (if available)</b>
10630	Phase 1 Trial of Iadademstat in Combination with Venetoclax and Azacitidine in Patients with Treatment Naïve AML	ETCTN-wide		Leukemia	Not available currently.
10636	Phase 1 Trial of CA-4948 in Combination with Pembrolizumab to Overcome Resistance to PD-1/PD-L1 Blockade in Metastatic Urothelial Cancer	ETCTN-wide		Genitourinary	Not available currently.
10657	Phase I/II Study to Evaluate the Feasibility and Efficacy of Sequential Abemaciclib and Gemcitabine Treatment in Patients with Retinoblastoma (Rb)+ Sarcomas	Limited		Sarcoma	Not available currently.
10674	A phase I study evaluating the safety of Cirtuvivint as monotherapy and in combination with ASTX727 and ASTX727 + venetoclax in patients with myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML)	ETCTN-wide		Leukemia	Not available currently.
10620	A Phase 1b Trial of Teclistamab in Combination with Iberdomide for Relapsed/Refractory Multiple Myeloma	ETCTN-wide		Myeloma	Not available currently.
10655	Phase I Clinical Trial of CA-4948 in Combination with FOLFOX Plus Bevacizumab as Frontline Treatment in Patients with Metastatic Colorectal Cancer	ETCTN-wide		Gastrointestinal	Not available currently.
10675	A Randomized Phase II Trial of ASTX727 +/- Iadademstat in Accelerated/Blast-Phase Philadelphia Chromosome-Negative Myeloproliferative Neoplasms (MPNs)	ETCTN-wide		Solid Tumors, NOS	Not available currently.

**All ETCTN Trials: Updated April 24, 2024 (Includes trials that are in review, approved, and active)**

<b>CTEP Trial ID</b>	<b><i>Title</i></b>	<b><i>Limited/ETCTN-wide</i></b>	<b><i>Radiation Oncology</i></b>	<b><i>Disease Area(s)</i></b>	<b><i>ClinicalTrials.gov website (if available)</i></b>
10664	Phase 1b/2 Study of Combination Tovorafenib and Rituximab Treatment in Classical Hairy Cell Leukemia	ETCTN-wide		Leukemia, Lymphoma	Not available currently. <span style="color: red;">New!</span>
10670	Phase 1 study of 5-fluorouracil in combination with abemaciclib in metastatic, refractory CRC	ETCTN-wide		Gastrointestinal	Not available currently. <span style="color: red;">New!</span>